By Allan Maurer

GAITHERSBURG, MD – MaxCyte, a company selling clinical and commercial cell modification technologies, has raised more than $1.12 million in equity and debt financing, according to a regulatory filing.

In a filing with the U.S. Securities and Exchange Commission, the company revealed it has secured at least $1,121,299 of a raise targeted at $1,250,000.

MaxCyte has not yet responded to TechJournal South’s request for an interview.

Founded in 1999, MaxCyte’s tranfection technology platform enables the discovery, development, manufacturing and delivery of innovative therapeutics for a wide range of diseases, according to the company.

The company says its technology allows the controlled modification of cell function and enables the development of therapies not otherwise commercializable.

MaxCyte’s clinical-grade cell loading technologies are fully developed with an FDA Master File in place, NIH RAC cleared, two Phase IIa trials on-going, two additional Phase II programs licensed and additional programs headed for clinical trials and commercialization, it reports on its Web site.

Medinet., LTD of Japan, commercially launched its therapeutic service enabled by MaxCyte’s technology for oncology patients in 2008.

Companies developing cell therapies partner with MaxCyte based upon its ability to create therapeutics that cannot otherwise be developed.

MaxCyte provides these partners with the ability to effectively manipulate cell function.

The company’s partners include Gergon, Medi Net, Northern Therapeutics, and Binex.

MaxCyte occupies a 14,000 sq ft facility in Gaithersburg, Maryland. More than 50% of the facility is dedicated to research and development.

Online: www.maxcyte.com

Southeast Venture Conference, February 29 – March 1, 2012 at the Ritz Carlton in Tysons Corner, VA – Where Smart Money Meets Smart People.
www.seventure.org

© 2009, TechJournal South. All rights reserved.